{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:23:13Z","timestamp":1789118593627,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the scientific research fund of aerospace center hospital","award":["YN202527"],"award-info":[{"award-number":["YN202527"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02175-3","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:27:19Z","timestamp":1781875639000},"page":"1787-1799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice"],"prefix":"10.1007","volume":"48","author":[{"given":"Li-Chao-Yue","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Heng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"2175_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017. https:\/\/doi.org\/10.3390\/jof3040057.","journal-title":"J Fungi"},{"issue":"8","key":"2175_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4065\/mcp.2011.0247","volume":"86","author":"RE Lewis","year":"2011","unstructured":"Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805\u201317. https:\/\/doi.org\/10.4065\/mcp.2011.0247.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2175_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","volume":"44","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44(3):183\u201393. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.019.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"2175_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080\u20137. https:\/\/doi.org\/10.1093\/cid\/cis599.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2175_CR5","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemotherapy. 2014;69(12):3294\u20139. https:\/\/doi.org\/10.1093\/jac\/dku313.","journal-title":"J Antimicrob Chemotherapy"},{"issue":"9","key":"2175_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919\u201334. https:\/\/doi.org\/10.1007\/s40265-013-0069-4.","journal-title":"Drugs"},{"issue":"12","key":"2175_CR7","first-page":"938","volume":"89","author":"SL Solomon","year":"2014","unstructured":"Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician. 2014;89(12):938\u201341.","journal-title":"Am Fam Physician"},{"issue":"Suppl 1","key":"2175_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002.","journal-title":"Clin Microbiol Infect"},{"key":"2175_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050645","author":"D Baracaldo-Santamar\u00eda","year":"2022","unstructured":"Baracaldo-Santamar\u00eda D, Cala-Garcia JD, Medina-Rinc\u00f3n GJ, et al. Therapeutic drug monitoring of antifungal agents in critically ill patients: is there a need for dose optimisation? Antibiotics. 2022. https:\/\/doi.org\/10.3390\/antibiotics11050645.","journal-title":"Antibiotics"},{"issue":"12","key":"2175_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","volume":"44","author":"Y Takesue","year":"2022","unstructured":"Takesue Y, Hanai Y, Oda K, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-asian and asian adult patients: consensus review by the japanese society of chemotherapy and the japanese society of therapeutic drug monitoring. Clin Ther. 2022;44(12):1604\u201323. https:\/\/doi.org\/10.1016\/j.clinthera.2022.10.005.","journal-title":"Clin Ther"},{"issue":"2","key":"2175_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bcp.15916","volume":"90","author":"X Hao","year":"2024","unstructured":"Hao X, Li Y, Zhang Y, et al. Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization. Br J Clin Pharmacol. 2024;90(2):440\u201351. https:\/\/doi.org\/10.1111\/bcp.15916.","journal-title":"Br J Clin Pharmacol"},{"key":"2175_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092181","author":"G Voulgaridou","year":"2023","unstructured":"Voulgaridou G, Paraskeva T, Ragia G, et al. Therapeutic drug monitoring (TDM) implementation in public hospitals in Greece in 2003 and 2021: a comparative analysis of TDM evolution over the years. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15092181.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2175_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00629-21","volume":"65","author":"E Kara","year":"2021","unstructured":"Kara E, Metan G, Bayraktar-Ekincioglu A, et al. Implementation of pharmacist-driven antifungal stewardship program in a tertiary care hospital. Antimicrob Agents Chemother. 2021;65(9):e0062921. https:\/\/doi.org\/10.1128\/aac.00629-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2175_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-024-00830-9","volume":"189","author":"R Fernandes","year":"2024","unstructured":"Fernandes R, Sabino R, Cunha C, et al. Multicentric study on the clinical mycology capacity and access to antifungal treatment in Portugal. Mycopathologia. 2024;189(1):15. https:\/\/doi.org\/10.1007\/s11046-024-00830-9.","journal-title":"Mycopathologia"},{"key":"2175_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1592767","author":"Q Yi","year":"2025","unstructured":"Yi Q, Dong L, Wang P, et al. Real-world correlation between therapeutic drug monitoring and clinical outcomes of the antifungal drug posaconazole: a single-center retrospective cohort study. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1592767.","journal-title":"Front Pharmacol"},{"issue":"Suppl 3","key":"2175_CR16","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1093\/infdis\/jiaa394","volume":"222","author":"MD Johnson","year":"2020","unstructured":"Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis. 2020;222(Suppl 3):S175-s198. https:\/\/doi.org\/10.1093\/infdis\/jiaa394.","journal-title":"J Infect Dis"},{"key":"2175_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/20420986221127503","volume":"13","author":"K Shen","year":"2022","unstructured":"Shen K, Gu Y, Wang Y, et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022;13:20420986221127503. https:\/\/doi.org\/10.1177\/20420986221127503.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"2175_CR18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s11192-017-2300-7","volume":"111","author":"NJ van Eck","year":"2017","unstructured":"van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053\u201370. https:\/\/doi.org\/10.1007\/s11192-017-2300-7.","journal-title":"Scientometrics"},{"issue":"12","key":"2175_CR19","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/s1473-3099(17)30316-x","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383\u201392. https:\/\/doi.org\/10.1016\/s1473-3099(17)30316-x.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2175_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14787210.2025.2539427","volume":"23","author":"YC Chen","year":"2025","unstructured":"Chen YC, Dhillon S, Adomakoh N, et al. The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios. Expert Rev Anti Infect Ther. 2025;23(10):969\u201383. https:\/\/doi.org\/10.1080\/14787210.2025.2539427.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"2175_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00134-025-07846-9","volume":"51","author":"R Liao","year":"2025","unstructured":"Liao R, Zheng X. Optimizing ICU antifungal therapy: overcoming pharmacokinetic limitations with combination strategies. Intensive Care Med. 2025;51(4):811\u20132. https:\/\/doi.org\/10.1007\/s00134-025-07846-9.","journal-title":"Intensive Care Med"},{"issue":"11","key":"2175_CR22","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1128\/aac.00970-16","volume":"60","author":"A Farkas","year":"2016","unstructured":"Farkas A, Daroczi G, Villasurda P, et al. Comparative evaluation of the predictive performances of three different structural population pharmacokinetic models to predict future Voriconazole concentrations. Antimicrob Agents Chemother. 2016;60(11):6806\u201312. https:\/\/doi.org\/10.1128\/aac.00970-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2175_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper(). Intensive Care Med. 2020;46(6):1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1.","journal-title":"Intensive Care Med"},{"issue":"6","key":"2175_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1164\/rccm.202207-1393OC","volume":"207","author":"K Shekar","year":"2023","unstructured":"Shekar K, Abdul-Aziz MH, Cheng V, et al. Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation. Am J Respir Crit Care Med. 2023;207(6):704\u201320. https:\/\/doi.org\/10.1164\/rccm.202207-1393OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2175_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/life15060946","author":"D Pe\u00f1a-Lorenzo","year":"2025","unstructured":"Pe\u00f1a-Lorenzo D, Rebollo N, S\u00e1nchez-Hern\u00e1ndez JG, et al. Optimization of Isavuconazole dosing in patients with invasive fungal infections through therapeutic drug monitoring: real-world clinical practice experience. Life Basel. 2025. https:\/\/doi.org\/10.3390\/life15060946.","journal-title":"Life Basel"},{"key":"2175_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01034-17","author":"AV Desai","year":"2017","unstructured":"Desai AV, Kovanda LL, Hope WW, et al. Exposure-response relationships for Isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.01034-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2175_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clinbiochem.2021.10.010","volume":"99","author":"R Tanaka","year":"2022","unstructured":"Tanaka R, Shiraiwa K, Takano K, et al. High-throughput simultaneousquantification offive azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry. Clin Biochem. 2022;99:87\u201396. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.10.010.","journal-title":"Clin Biochem"},{"key":"2175_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.talanta.2016.12.052","volume":"165","author":"L Qu","year":"2017","unstructured":"Qu L, Qian J, Ma P, et al. Utilizing online-dual-SPE-LC with HRMS for the simultaneous quantification of amphotericin B, fluconazole, and fluorocytosine in human plasma and cerebrospinal fluid. Talanta. 2017;165:449\u201357. https:\/\/doi.org\/10.1016\/j.talanta.2016.12.052.","journal-title":"Talanta"},{"issue":"11","key":"2175_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","volume":"26","author":"A G\u00f3mez-L\u00f3pez","year":"2020","unstructured":"G\u00f3mez-L\u00f3pez A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2020.05.037.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2175_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ftd.0000000000000952","volume":"44","author":"B Kably","year":"2022","unstructured":"Kably B, Launay M, Derobertmasure A, et al. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166\u201397. https:\/\/doi.org\/10.1097\/ftd.0000000000000952.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2175_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","volume":"113","author":"T Nakashima","year":"2021","unstructured":"Nakashima T, Inamoto Y, Fukushi Y, et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113(6):872\u20136. https:\/\/doi.org\/10.1007\/s12185-021-03105-x.","journal-title":"Int J Hematol"},{"issue":"4","key":"2175_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1060028020948174","volume":"55","author":"J Lee","year":"2021","unstructured":"Lee J, Ng P, Hamandi B, et al. Effect of therapeutic drug monitoring and Cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review. Ann Pharmacother. 2021;55(4):509\u201329. https:\/\/doi.org\/10.1177\/1060028020948174.","journal-title":"Ann Pharmacother"},{"key":"2175_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106405","volume":"184","author":"ZR Li","year":"2023","unstructured":"Li ZR, Shen CH, Li RD, et al. Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: a semiphysiologically based population pharmacokinetic modeling approach. Eur J Pharm Sci. 2023;184:106405. https:\/\/doi.org\/10.1016\/j.ejps.2023.106405.","journal-title":"Eur J Pharm Sci"},{"key":"2175_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2025-003429","author":"G Bayisa","year":"2025","unstructured":"Bayisa G, Edessa D, Deyasa M, et al. Enhancing senior physician-led multidisciplinary team rounds to improve patient care at Wallaga University Comprehensive Specialized Hospital, 2025. BMJ Open Qual. 2025. https:\/\/doi.org\/10.1136\/bmjoq-2025-003429.","journal-title":"BMJ Open Qual"},{"issue":"2","key":"2175_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106711","volume":"61","author":"A Veringa","year":"2023","unstructured":"Veringa A, Br\u00fcggemann RJ, Span LFR, et al. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial. Int J Antimicrob Agents. 2023;61(2):106711. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106711.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"2175_CR36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/tid.12454","volume":"17","author":"D Neofytos","year":"2015","unstructured":"Neofytos D, Ostrander D, Shoham S, et al. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. Transpl Infect Dis. 2015;17(6):831\u20137. https:\/\/doi.org\/10.1111\/tid.12454.","journal-title":"Transpl Infect Dis"},{"key":"2175_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.09.001","author":"S Botwright","year":"2024","unstructured":"Botwright S, Sittimart M, Chavarina KK, et al. Good practices for health technology assessment guideline development: a report of the health technology assessment international, HTAsiaLink, and ISPOR special task force. Value Health. 2024. https:\/\/doi.org\/10.1016\/j.jval.2024.09.001.","journal-title":"Value Health"},{"issue":"5","key":"2175_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13050130","volume":"13","author":"O Rose","year":"2025","unstructured":"Rose O, Egel C, Pachmayr J, et al. Pharmacist-led prescribing in Austria: a mixed-methods study on clinical readiness and legal frameworks. Pharmacy Basel. 2025;13(5):0130. https:\/\/doi.org\/10.3390\/pharmacy13050130.","journal-title":"Pharmacy Basel"},{"issue":"3","key":"2175_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17512433.2026.2638352","volume":"19","author":"AZ Al Meslamani","year":"2026","unstructured":"Al Meslamani AZ, Jarab AS, Merghani Ali Mohammed E. AI-enhanced therapeutic drug monitoring for vancomycin and \u03b2-lactam antibiotics in critical care: from population PK to bedside algorithms. Expert Rev Clin Pharmacol. 2026;19(3):239\u201354. https:\/\/doi.org\/10.1080\/17512433.2026.2638352.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"2175_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0891-z","volume":"19","author":"K Shekar","year":"2015","unstructured":"Shekar K, Roberts JA, McDonald CI, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19(1):164. https:\/\/doi.org\/10.1186\/s13054-015-0891-z.","journal-title":"Crit Care"},{"issue":"12","key":"2175_CR41","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40262-015-0297-8","volume":"54","author":"H Elewa","year":"2015","unstructured":"Elewa H, El-Mekaty E, El-Bardissy A, et al. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015;54(12):1223\u201335. https:\/\/doi.org\/10.1007\/s40262-015-0297-8.","journal-title":"Clin Pharmacokinet"},{"key":"2175_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01554-20","author":"JM Boonstra","year":"2021","unstructured":"Boonstra JM, M\u00e4rtson AG, Sandaradura I, et al. Optimization of Fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of Fluconazole in critically ill patients. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/aac.01554-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"2175_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00955-18","author":"L Hu","year":"2018","unstructured":"Hu L, Dai TT, Zou L, et al. Therapeutic drug monitoring of Voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.00955-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2175_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jac\/dkae003","volume":"79","author":"T Lai","year":"2024","unstructured":"Lai T, Yeo CY, Rockliff B, et al. Therapeutic drug monitoring of liposomal amphotericin B in children. are we there yet? A systematic review. J Antimicrob Chemother. 2024;79(4):703\u201311. https:\/\/doi.org\/10.1093\/jac\/dkae003.","journal-title":"J Antimicrob Chemother"},{"key":"2175_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106506","volume":"188","author":"L Cheng","year":"2023","unstructured":"Cheng L, Zhao Y, Liang Z, et al. Prediction of plasma trough concentration of voriconazole in adult patients using machine learning. Eur J Pharm Sci. 2023;188:106506. https:\/\/doi.org\/10.1016\/j.ejps.2023.106506.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2175_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107424","volume":"65","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhou Y, Liu D, et al. Comparison of population pharmacokinetic modeling and machine learning approaches for predicting voriconazole trough concentrations in critically ill patients. Int J Antimicrob Agents. 2025;65(2):107424. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107424.","journal-title":"Int J Antimicrob Agents"},{"key":"2175_CR47","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.2147\/dddt.S495050","volume":"19","author":"R Liu","year":"2025","unstructured":"Liu R, Ma P, Chen D, et al. A real-time plasma concentration prediction model for Voriconazole in elderly patients via machine learning combined with population pharmacokinetics. Drug Des Devel Ther. 2025;19:4021\u201337. https:\/\/doi.org\/10.2147\/dddt.S495050.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2175_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpt.1907","volume":"109","author":"I Bica","year":"2021","unstructured":"Bica I, Alaa AM, Lambert C, et al. From real-world patient data to individualized treatment effects using machine learning: current and future methods to address underlying challenges. Clin Pharmacol Ther. 2021;109(1):87\u2013100. https:\/\/doi.org\/10.1002\/cpt.1907.","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02175-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:05Z","timestamp":1789117085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02175-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02175-3","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}